We are very pleased to say that five articles from the CEBD appear among the top 25 highest rated dermatology articles over the last year in the current awareness service EvidenceUpdates from BMJ (http://plus.mcmaster.ca/evidenceupdates).
EvidenceUpdates assesses the quality of newly published articles, and then they are rated for clinical relevance and interest by an international panel of specialists. The aim is to alert clinicians to the current best evidence from research to support evidence-based decision making.
Our paper in Lancet Oncology on the results of the SINS trial on surgical excision versus imiquimod for BCC was the second highest rated paper under the Dermatology specialty, while the preliminary results of the BEEP study on emollients to prevent atopic dermatitis just published in the Journal of Allergy and Clinical Immunology came in at number 11. Three Cochrane Reviews were also in the top 25. The review on topical antifungal treatments for tinea was at number 7, and the reviews on topical anti-inflammatory agents for seborrhoeic dermatitis and psychological and educational interventions for atopic eczema in children were at number 15 and 22 respectively.
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Lancet Oncol. 2014 Jan;15(1):96-105.
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.
J Allergy Clin Immunol. 2014 Oct;134(4):818-23
Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp.
Cochrane Database Syst Rev. 2014 May 19;5:CD009446.
Topical antifungal treatments for tinea cruris and tinea corporis.
Cochrane Database Syst Rev. 2014 Aug 4;8:CD009992.
Psychological and educational interventions for atopic eczema in children.
Cochrane Database Syst Rev. 2014 Jan 7;1:CD004054.
Posted on Wednesday 12th November 2014